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Abstract
Chronic hepatitis C virus (HCV) infection can lead to advanced liver disease (AdvLD), including cirrhosis, decompensated
cirrhosis, and liver cancer. The aim of this study was to determine recent historical rates of HCV patient progression to
AdvLD and to project AdvLD prevalence through 2015. We first determined total 2008 US chronic HCV prevalence from the
National Health and Nutrition Evaluation Surveys. Next, we examined disease progression and associated non-
pharmacological costs of diagnosed chronic HCV-infected patients between 2007–2009 in the IMS LifeLink and CMS
Medicare claims databases. A projection model was developed to estimate AdvLD population growth through 2015 in
patients diagnosed and undiagnosed as of 2008, using the 2007–2009 progression rates to generate a ‘‘worst case’’
projection of the HCV-related AdvLD population (i.e., scenario where HCV treatment is the same in the forecasted period as
it was before 2009). We found that the total diagnosed chronic HCV population grew from 983,000 to 1.19 million in 2007–
2009, with patients born from 1945–1964 accounting for 75.0% of all patients, 83.7% of AdvLD patients, and 79.2% of costs
in 2009, indicating that HCV is primarily a disease of the ‘‘baby boomer’’ population. Non-pharmacological costs grew from
$7.22 billion to $8.63 billion, with the majority of growth derived from the 60,000 new patients that developed AdvLD in
2007–2009, 91.5% of whom were born between 1945 and 1964. The projection model estimated the total AdvLD
population would grow from 195,000 in 2008 to 601,000 in 2015, with 73.5% of new AdvLD cases from patients
undiagnosed as of 2008. AdvLD prevalence in patients diagnosed as of 2008 was projected to grow 6.5% annually to
303,000 patients in 2015. These findings suggest that strategies to diagnose and treat HCV-infected patients are urgently
needed to increase the likelihood that progression is interrupted, particularly for patients born from 1945–1964.
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Introduction
While some patients initially infected with hepatitis C virus
(HCV) spontaneously clear the infection and become HCV RNA
negative, the majority (,70%) of patients become chronically
infected [1], [2], [3]. The incidence of new HCV infections has
recently been low and declining [4], with the implementation of
routine blood screening decreasing transfusion-related infection
[5]. As a result, intravenous drug use is now the primary cause of
transmission, with sexual transmission playing a lesser role [5], [6].
Historical incidence trends point towards a wave of HCV
infections occurring in individuals born between 1945 and 1964
(i.e., the ‘‘baby boomer’’ population), [3], [7] resulting in a total
United States (US) prevalence estimated to approach 4 million
patients, [8], [9] with many infected individuals having lived with
latent disease for decades. The US prevalent population may
surpass 5 million if homeless, institutionalized, and military
patients are included [10]. HCV has been associated with
increased mortality regardless of the extent of liver disease [9],
[11], and deaths from HCV now surpass HIV-associated mortality
in the US [12]. The longer a patient is chronically infected with
HCV, the higher the chance of progression to advanced liver
disease (AdvLD), namely cirrhosis, decompensated cirrhosis, and
liver cancer [2]. Approximately 20% of chronically infected
patients develop cirrhosis within 20 to 30 years of the initial
infection [3], [13], [14], [15], although there is some variability
across specific subpopulations, with certain co-factors (e.g., age,
HCV genotype 3 infection, alcohol abuse, diabetes) contributing
to more rapid progression [16], [17], [18], [19], [20], [21], [22].
Patients who progress to decompensated cirrhosis may present
with potentially life-threatening complications (e.g., hepatic
encephalopathy) [15], and become candidates for liver transplan-
tation. For liver transplantation in the US, HCV is implicated in
two ways: i) it is the leading indication for liver transplantation in
the US (39% in 2006), [23] and ii) it is one of the leading causes of
liver cancer, another key indicator for transplant (23%) [24].
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The medical burden associated with HCV translates into a
substantial cost burden to the US healthcare system as well,
although there are few recent studies. In one historical study, total
cost related to HCV infection in the US was estimated at $5.5
billion in 1997, with about a third attributed to direct medical
costs [25]. Another study estimated the total direct healthcare cost
at more than $1 billion for 1998 [8]. A more recent analysis found
that all-cause per HCV-infected patient costs have been rising and
the annual all-cause costs per patient ($20,961) between 2002–
2006 were nearly four-fold greater than that of matched controls
($5,451) [26]. In view of the high and growing morbidity and costs
associated with HCV, several studies have recently focused on
demonstrating how increased diagnosis and new treatment
modalities could have a positive influence on patient- and cost-
related outcomes [27], [28], [29], [30], e.g., the initiation of a birth
cohort-focused screening HCV program that complements a
behavioral risk-driven approach would be highly cost-effective and
would substantially increase chronic HCV diagnosis rates.
The aim of this study was to determine the recent burden of
HCV, especially HCV-associated AdvLD, in the US using
adjudicated claims data, and project it forward through 2015.
We began by estimating the US prevalence of chronic HCV in
2008. Next, we used historical medical claims data from 2007–
2009 to determine the prevalence and the non-pharmacological
treatment costs of civilian, non-institutionalized non-AdvLD and
AdvLD patients in this time period. We then projected AdvLD
prevalence in the US chronic HCV population through 2015
based on progression and mortality rates observed in the claims
data. Our dynamic progression model represents the ‘‘worst case’’
scenario where historical screening/diagnosis rates and no
treatment beyond therapies available prior to 2009 is applied.
The model uses progression rates derived directly from 2007–2009
claims data of HCV-infected patients who may or may not have
been treated with antiviral therapy available at that point of time.
Thus, it represents the scenario where diagnosis and treatment of
HCV-infected patients is the same in the forecasted period
through 2015 as it was prior to 2009. This ‘‘worst case’’ scenario
portrays the situation in the absence of direct-acting antivirals
and/or new screening programs that use other co-factors other
than those currently used to identify at-risk patients (e.g.,
intravenous drug users). The intent is to highlight the urgency of
identifying currently undiagnosed patients and effectively treating
both currently diagnosed and undiagnosed patients with state-of-
the-art antiviral treatment, as lack of treatment can result in a
large number of patients progressing to AdvLD and incurring
significant healthcare costs during the foreseeable period.
Although previous studies have estimated the future prevalence
and cost of chronic HCV infection in the US, [31], [32], [33],
[34], [35], [36], this is the first study to derive HCV-related
AdvLD prevalence, disease progression, and mortality rates using
recent adjudicated claims data.
Materials and Methods
Estimation of US HCV Population
The total US HCV prevalence, and the viremic (i.e., chronic)
HCV prevalence were estimated using data from the 2005–06 and
2007–08 National Health and Nutrition Evaluation Survey
(NHANES) [37], in which a total of 19,712 survey participants
were sampled during the two iterations used in this study. The
NHANES dataset is a publicly available resource that can be
downloaded without cost from the CDC website. HCV prevalence
was determined by a positive test for HCV antibody, and the
prevalence of chronic HCV infection was determined by a positive
HCV RNA test result. The HCV antibody and RNA test data
were obtained from the 2005–06 and 2007–08 NHANES survey
Laboratory files. Using data from the 2005–06 and 2007–08
NHANES survey Questionnaire files, chronic HCV-infected
patients were further categorized into undiagnosed and diagnosed
based on their awareness of a previous diagnosis.
Analysis of Claims Data
To estimate the number of chronic HCV-infected patients in
the US Medicare system and their stage of disease, data were
obtained from the 2007–2009 CMSMedicare claims database and
the LifeLink claims database (IMS LifeLink: Health Plan Claims
Database, all rights reserved). The CMS claims data is a publicly
available limited data set that can be downloaded from the CMS
website, and covers the US population aged 65 and over, patients
of all ages who are disabled, those with end-stage renal disease
(ESRD), and those who are on Social Security or receiving
Railroad retirement benefits [38]. It comprises 100% of the 5-year
Medicare claims data for both outpatient and inpatient institu-
tional settings and 5% of the carrier data from the physician office
setting, which was projected to national equivalents. The LifeLink
claims database (acquired from IMS Health Incorporated)
includes patients ,65 years old that were commercially or self-
insured, receiving assistance from a State Children’s Health
Insurance Program (SCHIP), commercially sponsored Medicaid
plans, and commercially sponsored Medicare plans not included in
the Medicare data.
The data was analyzed using SQL Server to create a relational
database that utilized a de-identified patient number as the
common identifier. Patients with HCV were defined as having an
HCV-related ICD-9-CM diagnosis code on a claim in any given
year. HCV patient claims were further analyzed for AdvLD using
ICD-9-CM diagnosis codes (see Table S1 for the ICD-9-CM codes
used). HCV patient claims were divided into five-year birth
cohorts except for those born after 1984, who were excluded from
the 5-year cohort analysis due to small sample size. Annual costs
for a patient were determined only if the patient had an HCV-
related claim in that year. If so, then reimbursed amounts were
totaled for all claims where ICD-9-CM codes for HCV and/or
AdvLD were indicated as either the primary or secondary
diagnosis. LifeLink patient and reimbursed cost data were indexed
to 2007 to control for differences in LifeLink enrollment numbers
each year. All numbers from the LifeLink analysis were projected
to the non-Medicare diagnosed chronic HCV population total.
HCV Patient Disease Progression Rates (2008–2009)
IMS LifeLink claims data from 2007–2009 were used to
calculate disease progression rates by conducting a retrospective
cohort study that analyzed HCV-diagnosed patients with or
without AdvLD. Patients were followed for one year (from 2008 to
2009) to determine whether they progressed to a different disease
state. The rates were derived from the percentage of patients with
an HCV-related disease state in 2008 that progressed to another
HCV-related disease state in 2009 based on the patient
progression rules shown in Figure S1, whereby patients only
progress to more severe complications, with the exception of
patients with decompensated cirrhosis reverting back to cirrhosis.
To ensure an adequate number of events were present in the data
to enable accurate calculation of progression rates to less common
AdvLD states, patients were divided into three age cohorts (,45
years old, 45–64 years old, and 65+ years old). Patient status in
2007 was used to determine whether they were newly diagnosed or
existing patients, and also helped define the patient’s status in
US Chronic HCV Population Disease Progression
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2008. All patients who were undiagnosed as of 2008 were assumed
to be non-AdvLD patients.
HCV Patient All-Cause Mortality Rates (2008)
Medicare claims data from 2008 were used to determine
mortality rates for each HCV-related disease state, divided into 5-
year age cohorts, by calculating the percentage of patients that
died during the calendar year (Figure S2). As such, these mortality
rates only reflect the diagnosed HCV population. The Medicare
HCV population mortality rate was calibrated to that of the
general population by dividing the total US mortality rate
(obtained from 2007 US Census Bureau data [39]) by the total
Medicare mortality rate; this factor was used to determine the
mortality rates to be used in the progression model described
below.
Projection of AdvLD Progression (2008–2015)
A dynamic patient progression modeling framework was
constructed using Microsoft ExcelH (Figure S3). The model
predicted the evolution of the diagnosed and undiagnosed HCV-
infected population from 2008 onwards based on the age-matched
progression and mortality rates outlined above. All chronic HCV-
infected patients who were undiagnosed as of 2008 were assumed
to be non-AdvLD as a conservative estimate. Liver transplants
were kept constant at 2,400 per year. The model also assumed that
undiagnosed patients had the same age distribution as the
diagnosed population in 2008, which was validated by an analysis
of the NHANES data used to estimate the US HCV population
(Figure S4).
Projection Model Sensitivity Analysis
The sensitivity of the projection model described above to the
starting number and distribution of non-AdvLD/AdvLD patients
was tested by replacing the 2008 diagnosed HCV population with
the analogous values determined for the non-AdvLD/AdvLD
population distributions in 2007 or 2009 (see Table S2).
Concomitantly, the 2008 undiagnosed HCV population was
replaced with calculated values for undiagnosed HCV patients in
2007 or 2009, which were derived from the 2008 value by
adjusting for annual chronic HCV incidence [40], mortality rates
of undiagnosed HCV patients (based on the rates for diagnosed
non-AdvLD patients previously described), and the number of
diagnosed HCV patients in 2008 compared to 2007 and 2009.
The 2015 AdvLD population derived from replacement of the
2008 HCV population with 2007 or 2009 was compared the
original value based on 2008 to ascertain the validity of our model
projections and statistical analyses.
Results
Estimated 2008 US HCV Population
Of the 2008 US Census 16–85 year old population of 232.9
million [41], 3.57 million (a total prevalence of 1.53%) were
estimated to have been infected with HCV at some point based on
the 2005–06 and 2007–08 NHANES studies (Figure S5) [37]. An
estimated 2.68 million (75.1%) of the population had chronic
HCV in 2008 (i.e., were viremic). This group was further
segmented into 1.10 million diagnosed patients, and the remaining
1.58 million (59%) who were undiagnosed at the time of the
NHANES study.
Overall US HCV Population and Cost Dynamics
The estimated diagnosed US HCV population grew from
983,000 to 1.19 million in 2007–2009 (annual growth rate of
10.1%; see Figure S6). AdvLD population growth totaled 60,000
new patients (annual rate of 16.6%), outpacing that of the non-
AdvLD population (8.7%) in the two-year period. By 2009,
AdvLD patients accounted for 19.1% of the diagnosed HCV
population, compared to 17.0% in 2007. Decompensated cirrhosis
and cirrhosis were the most common forms of AdvLD, comprising
46.6% and 36.5% of the 2009 AdvLD HCV population,
respectively, and contributed the majority of the 60,000 new
AdvLD patients in 2009 (30,000 and 18,000 new patients,
respectively).
In a similar manner to the growth in the HCV population, the
overall non-pharmacological cost burden of HCV-infected
patients grew from $7.22 billion in 2007 to $8.63 billion in 2009
at an annual growth rate of 9.4% (Figure S6), a substantially
higher growth rate than for total US healthcare costs over the
same period (4.3%) [42]. Analogous to patient growth, cost growth
was higher in the AdvLD cohort (13.2%) compared to non-
AdvLD (4.0%).
The birth cohort analysis revealed that patients born in 1945–
64 were the largest age group among the different age groups and
that they are rapidly progressing to AdvLD. This cohort
accounted for 75.0% of all HCV-infected patients in 2009
(Figure 1A), and in the AdvLD population the concentration of
patients born in 1945–64 is even more striking, with 83.7% of
patients belonging to this age group. This cohort experienced
particularly rapid progression to advanced disease, highlighted by
the 1955–59 group, where the AdvLD population increased by
22.9% annually (see Table S3 for growth rates by disease state for
each cohort). The 1945–64 cohort also contributed the vast
majority (91.5%) of new AdvLD patients.
Analysis of cost data by birth cohort revealed that the 1945–
1964 birth cohort accounted for 79.2% of total and 85.9% of
AdvLD-related costs in 2009. All groups except for the three oldest
cohorts experienced increased costs in 2009 compared to 2007
(Figure 1B). Generally, the growth in AdvLD costs exceeded that
of the non-AdvLD group (see top two rows of table in Figure 1B).
The contribution of AdvLD patients to overall cost increases
peaked amongst the four middle-aged cohorts. Among AdvLD
categories, decompensated cirrhosis contributed the greatest
proportion of total cost (29.2%) in 2009, despite representing
only 8.9% of patients (Table 1).
In contrast to the other groups, the three oldest birth cohorts
experienced decreases in the number of patients and totals costs
between 2007–09 (see Figures 1A and 1B), likely as a result of the
increased all-cause mortality rate in this older population (see
Figure S2). Across these three cohorts, the total HCV population
decreased by 11,000 between 2007–09 (annual rate of 29.3%),
with a concomitant drop in HCV-related non-pharmacological
treatment costs from $576 million in 2007 to $503 million in 2009
(annual rate of 26.5%). Separating into different disease status,
AdvLD and non-AdvLD patient populations decreased at similar
annual rates (29.5% and 29.3% respectively), however there was
a more substantial annual cost decrease in the non-AdvLD group
(210.1%) compared to the AdvLD cohort (24.8%).
Disease Progression Rates in the HCV Patient Population
For all patients, disease progression rates in 2008–2009 between
the various AdvLD states were much higher than for patients
progressing from non-AdvLD to an AdvLD state (Tables 2, 3, 4).
In the ,45 year old cohort, 1.6% of non-AdvLD patients
progressed to AdvLD annually, which increased to 4.4% and 5.2%
in the 45–64 and 65+ year old cohorts respectively. By
comparison, progression of HCV-related cirrhosis patients to
decompensated cirrhosis alone occurred at rates of 5.1%, 11.5%
US Chronic HCV Population Disease Progression
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Figure 1. Total non-AdvLD/AdvLD patients and costs and their 2007–2009 growth. (A) Total non-AdvLD/AdvLD patients and their 2007–
2009 growth rates by birth cohort. (B) Total non-AdvLD/AdvLD costs and their 2007–2009 growth rates by birth cohort.
doi:10.1371/journal.pone.0063959.g001
US Chronic HCV Population Disease Progression
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and 8.8% in the ,45, 45–64 and 65+ year old cohorts,
respectively. In all three cohorts, both the forward and ‘‘reverse’’
progressions between cirrhosis and decompensated cirrhosis were
similar. This is to be expected as decompensation is a potentially
reversible complication of cirrhosis.
All-Cause Mortality Rates in the HCV Patient Population
Two key trends emerged from the analysis of mortality rates in
the Medicare 2008 HCV population. First, annual all-cause
mortality increased with patient age across all HCV-related
disease states (Figure S2). Second, mortality rates increased as the
severity of AdvLD increased, with decompensated cirrhosis and
liver cancer having the highest annual all-cause mortality rates,
exceeding .20% for patients aged 74+ years old. Patients with
cirrhosis, the mildest form of AdvLD, have mortality rates higher
than those of non-AdvLD patients across all age cohorts. For
patients born before 1945, annual all-cause mortality outpaced
disease progression, resulting in a lower overall proportion of
AdvLD patients in this cohort (see bottom row of table in
Figure 1A).
Projected AdvLD Prevalence through 2015 in HCV-
infected Patients Diagnosed and Undiagnosed as of 2008
In the absence of potential increases in disease screening,
treatment or treatment success rates, the overall AdvLD patient
population was projected to grow from 195,000 to 601,000
between 2008 and 2015, largely as a result of rapid progression of
AdvLD among the 2008 undiagnosed HCV-infected population
(Figure 2). The majority (73.5%) of the 406,000 new AdvLD
patients that are expected to emerge by 2015 originate from the
patient population that was undiagnosed as of 2008. Thus, by
2015 the AdvLD patient population is projected to be almost
equally derived from HCV-infected patients who were undiag-
nosed and diagnosed in 2008. While growth was projected to be
slower in AdvLD patients who were diagnosed as of 2008, this
population will still increase at 6.5% annually to reach 303,000
patients by 2015. Within AdvLD, cirrhosis and decompensated
cirrhosis patients are projected to represent the majority of AdvLD
patients by 2015, and account for 80.2% and 90.4%, respectively
of the AdvLD population among patients who were diagnosed or
undiagnosed as of 2008 (Figure 3A–B).
Projection Model Sensitivity Analysis
The sensitivity ofour projection model to the starting number
and non-AdvLD/ALD distribution of patients was tested by
replacing the 2008 diagnosed and undiagnosed HCV populations
with the equivalent populations determined for 2007 and 2009.
Using 2007 patient numbers resulted in a total AdvLD population
of 588,000 in 2015, 2% lower than the 601,000 AdvLD patients in
the original projection. Conversely, using 2009 patient numbers
afforded a total AdvLD population of 616,000 in 2015, 3% higher
than the original projection.
Discussion
This retrospective analysis of real-world US HCV-associated
non-pharmacologic 2007–2009 claims data indicates that a large
increase in the number of patients with HCV-associated AdvLD,
especially those born in 1945–1964 (i.e., ‘‘baby boomers’’), may
significantly impact the US healthcare system in the coming years
if HCV-infected patients are left undiagnosed and/or untreated.
Specifically, many patients who were undiagnosed as having HCV
as of 2008 may present with AdvLD by the year 2015.
First, and in line with previous estimates, our analysis of the
2005–2006 and 2007–2008 NHANES datasets showed HCV
prevalence of 3.57 million people in the 16–85-year old US
Table 1. Percentage contribution of each HCV disease state to 2009 total patients and costs.
Non-AdvLD Cirrhosis
Decomp.
Cirrhosis* Liver Cancer Liver Transplant Liver C/T**
% Contribution to Total Patients 80.9% 7.0% 8.9% 1.5% 1.3% 0.4%




Table 2. Annual progression rates by HCV patient disease status in the ,45 y.o. age cohort.
Resultant Patient Disease State







Non-AdvLD 0.78% 0.68% 0.03% 0.03% 0.03%
Cirrhosis N/A 5.10% 1.02% 0.03% 0.03%
Decomp. Cirrhosis* 3.25% N/A 0.65% 1.30% 0.03%
Liver Cancer N/A N/A N/A N/A 0.03%
Liver Transplant N/A N/A N/A N/A 0.03%
*Decomp. = decompensated.
doi:10.1371/journal.pone.0063959.t002
US Chronic HCV Population Disease Progression
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population in 2008, and within this group, 2.68 million who were
chronically infected. This estimate of chronic HCV prevalence
was similar to one based on 1988–1994 NHANES data (2.7
million patients) [43], and somewhat lower than two previous
studies based on the earlier 1999–2002 NHANES data (3.2–3.3
million patients) [32] [44], which may have resulted from the use
of different NHANES datasets and patient projections. The
proportion of the chronically-infected HCV population with
AdvLD determined in this study (17.0% in 2007, increasing to
19.1% in 2009) was analogous to another recent report showing
that 20% of diagnosed HCV-infected patients had AdvLD based
on claims data from 1998–2006 [45]. Population-based models
previously projected the total number of AdvLD cases to reach
800,000 by 2009, of which approximately 20,000 were expected to
have decompensated cirrhosis [32]. Our retrospective analysis
covers only diagnosed HCV-infected patients and shows a lower
total number of AdvLD cases but a greater occurrence of
decompensated cirrhosis, exceeding 100,000 cases in 2009.
In parallel with increasing AdvLD prevalence, the HCV-
associated non-pharmacological costs increased at an annual rate
of 9.4% from 2007–2009, more than doubling the 4.3% overall
growth in US healthcare costs in the same period [42]. The cohort
born between 1945–1964 was again the primary driver of this
growth. Because AdvLD development is a function of time lived
with the virus, the cost of treating HCV is likely to grow further as
the large 1945–1964 birth cohort continues to age. Importantly
and perhaps surprisingly, commercial payers are likely to incur
most of these costs, since the majority of the patients in the 1945–
1964 birth cohort are mostly covered by commercial insurance
and are at least several years away from reaching Medicare
eligibility.
Our progression model projected significant growth in the US
HCV disease burden over the next several years in the absence of
diagnosis and treatment beyond those available prior to 2009. In
the model, which used progression and mortality rates determined
during a time period when pegylated interferon and ribavirin (Peg-
IFN/RBV) was the standard of care (i.e., no protease inhibitors),
the total AdvLD population would grow rapidly, from 195,000 to
601,000 between 2008–2015, with 73.5% of the new AdvLD
patients undiagnosed as of 2008. In the population diagnosed as of
2008, AdvLD was projected to be prevalent in 33.2% of patients in
2015, compared to 17.8% in 2008. The total population of
patients with cirrhosis was projected to grow from 70,000 to
285,000 in 2015, creating a much larger pool of patients that could
progress to decompensated cirrhosis after 2015, exposing the
healthcare system to further elevation of costs. The HCV-related
decompensated cirrhosis population itself is projected to reach
228,000 patients by 2015, which exceeds the ,125,000 patients
estimated in previous studies, [32], [34] suggesting a significantly
faster progression of chronic HCV-infected patients to decom-
pensated cirrhosis than was previously anticipated. The model
further projected that all-cause mortality would also accelerate
Table 3. Annual progression rates by HCV patient disease status in the 45–64 y.o. age cohort.
Resultant Patient Disease State







Non-AdvLD 2.23% 1.81% 0.25% 0.05% 0.01%
Cirrhosis N/A 11.45% 2.37% 0.49% 0.33%
Decomp. Cirrhosis* 11.56% N/A 1.38% 2.33% 0.45%
Liver Cancer N/A N/A N/A N/A 9.16%
Liver Transplant N/A N/A N/A N/A 5.84%
*Decomp. = decompensated.
doi:10.1371/journal.pone.0063959.t003
Table 4. Annual progression rates by HCV patient disease status in the 65+ y.o. age cohort.
Resultant Patient Disease State







Non-AdvLD 2.51% 2.31% 0.34% 0.00% 0.00%
Cirrhosis N/A 8.75% 3.13% 0.00% 0.00%
Decomp. Cirrhosis* 7.37% N/A 2.15% 2.30% 0.00%
Liver Cancer N/A N/A N/A N/A 5.41%
Liver Transplant N/A N/A N/A N/A 4.76%
*Decomp. = decompensated.
doi:10.1371/journal.pone.0063959.t004
US Chronic HCV Population Disease Progression
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Figure 2. Projected 2008–2015 AdvLD prevalence in HCV-infected patients who were diagnosed and undiagnosed as of 2008,
respectively.
doi:10.1371/journal.pone.0063959.g002
Figure 3. Projected 2008–2015 populations for each AdvLD state in HCV-infected patients. (A) Patients diagnosed as of 2008. (B) Patients
undiagnosed as of 2008.
doi:10.1371/journal.pone.0063959.g003
US Chronic HCV Population Disease Progression
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because patients with decompensated cirrhosis and liver cancer
experience a 3- to 10-fold increase in mortality compared to non-
AdvLD patients. These findings reveal the importance of
establishing integrated programs that expand current diagnosis
programs to a wider population, increase physician referral, and
utilize direct-acting antivirals as the standard of care for HCV
pharmacological therapy due to their higher efficacy [46] and
broader treatment inclusion criteria, so that the morbidity,
mortality and costs associated with progression to AdvLD are
better controlled.
The use of adjudicated Medicare and commercial medical
claims allowed us to determine real-life HCV population
dynamics. However, this study faced some limitations inherent
to the nature of these datasets. The time-limited and observational
nature of the claims data did not allow for ascertainment of
causality between HCV infection and the presence of an AdvLD
condition. Further, only non-pharmacological costs were included
in the cost estimates, which may underestimate the true total cost
(i.e., medical and pharmacy costs) associated with chronic HCV
and AdvLD complications. Conversely, the inclusion of claims
where HCV and/or AdvLD is a secondary diagnosis may have led
to an overestimation of total non-pharmacological costs related to
the treatment of HCV and AdvLD. In addition, the progression
model for HCV disease in this study did not include treatment
intervention or any efforts to proactively screen at-risk patients
undiagnosed as of 2008. Progression rates in this model accounted
for current co-factors related to disease progression at a
population-wide level using 2007–2009 rates; co-factors that could
potentially emerge after 2009 were not considered. It therefore
portrays a ‘‘worst case’’ scenario in the absence of direct-acting
antivirals and/or new screening programs compared with those in
existence prior to 2009. However, we also took a conservative
approach by operationally defining all undiagnosed HCV-infected
patients as of 2008 to be non-AdvLD, even though HCV-related
cirrhosis can be completely asymptomatic [15], so as to avoid
overestimating present and projected AdvLD prevalence. Our
projection model, which was based on the diagnosed and
undiagnosed HCV populations ascertained from recent historical
claims and NHANES data, gave similar projections of the 2015
AdvLD population when the initial model year’s population values
was changed from 2008 to 2007 or 2009. This finding supports the
validity of our modeling methodology and statistical analysis for
the desired estimation of the ‘‘worst case’’ 2015 AdvLD
population.
Overall, this analysis supports recent studies pointing to the
urgent need for increased efforts to diagnose and treat chronic
HCV. Considering the morbidity, mortality and cost associated
with AdvLD [8], [11], these patients will present a significant
burden to the healthcare system if appropriate steps are not
undertaken to identify them for treatment with direct-acting
antiviral therapy, which is the current standard of care for HCV
treatment. Recent analyses projected that treatment with direct-
acting antivirals plus Peg-IFN/RBV is a cost-effective intervention
for reducing the lifetime risk of AdvLD in genotype 1 HCV-
infected patients and improving quality adjusted life years (QALY)
[27]. Even Peg-IFN/RBV treatment alone has demonstrated
decreased all-cause mortality in US veteran [47] and Canadian/
European tertiary care center [48] populations, or a cost-effective
increase in QALY [49], [50]. It is important to note that the
treatment-induced SVR in these studies does not necessarily
decrease all-cause mortality to that of the general population, as
these cohorts (e.g. US veterans) may have other co-morbidities
that contribute to a higher all-cause mortality rate as they age.
Our study also highlights the public health concern associated
with the low rate of HCV diagnosis in the community. Given that
less than half of the 2.7 million chronic HCV-infected patients
were diagnosed in 2008, the substantial amount of disease
progression seen in the 2007–2009 historical claims data only
foreshadows the possibility of a larger future impact of HCV on
the US population [32]. Our analysis shows that most patients
who may potentially progress to AdvLD by 2015 will be from the
group undiagnosed as of 2008. The vast majority of these patients,
in turn, will come from the 1945–1964 birth cohort. Because HCV
infection can be asymptomatic even in patients with cirrhosis [15],
and risk-based screening is ineffective [12], many chronic HCV-
infected patients may not become diagnosed until they present
with severe AdvLD complications. Screening programs that
identify and provide treatment for undiagnosed patients have the
potential to lessen total HCV cost burden by decreasing the
volume of patients requiring expensive treatment for HCV-related
AdvLD and reducing their high mortality rate. The impact of
screening programs is supported by recent studies [28], [29],
highlighting the cost-effectiveness of HCV screening in the 1945–
1964 birth cohort, which is shown here to have the highest
potential burden of HCV complications. Indeed, the CDC
recently recommended that all individuals born from 1945–1964
(‘‘baby boomers’’) receive a one-time test for HCV [51], [52].
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